Search Results for “Alzheimer” – Page 7 – media

Monoclonal Antibody Delays Cognitive Decline, Erases Alzheimer’s Plaques in Phase 2 Trial

A phase 2 study on BAN2401, a monoclonal antibody that hits soluble amyloid beta oligomers, showed that it limits cognitive decline in patients with slight cognitive injury or premature Alzheimer’s dementia on two scales and removed brain amyloid in 81% of patients in the trial.
- Source: MDEdge
- 1,027
- July 30, 2018
Alzheimer's disease Clinical Trials FDA
Fatty Diet and Liver Function Impact Risk of Alzheimers

Risk of Alzheimer's disease increases with reduction in levels of plasmalogens, a class of lipids produced by the liver that constitute cell membranes in the brain, confirms new research presented at the Alzheimer's Association International Conference (AAIC) 2018 by Mitchel A. Kling, MD, an associate professor of Psychiatry in the Perelman School of Medicine at the University of Pennsylvania and the Veterans Affairs Medical Center.
- Source: ScienceDaily
- 716
- July 29, 2018
Alzheimer's disease diet Researches
Rise in Shares for Biogen, Eisai as Alzheimer’s Drug Succeeds in Mid-Stage Trial.

In a breakthrough finding, revealed through the final analysis of a mid-stage trial, Japanese pharmaceutical firm, Eisai Co and Biogen Inc’s drug for Alzheimer’s proved beneficial for patients who received the highest dose.
- Source: Reuters
- 723
- July 9, 2018
Alzheimer's disease Eisai Market Views
Target Identification for Drug Development Against Alzheimer Disease

In a research study led by Yuksel Agca, associate professor of veterinary pathology and a researcher in the Comparative Medicine Program in the MU College of Veterinary Medicine, it was found that two proteins namely APP and PS1, were the key factors linked to Alzheimer’s disorder, by carrying out the research work in rat model. If the accumulation of amyloid-β could be manipulated, it could lead to a decrease in the onset of Alzheimer Disease.
- Source: medicalxpress
- 597
- June 8, 2018
Alzheimer's disease Researches
EIP Pharma bags $20.5M to support Alzheimer’s drug through phase 2

EIP Pharma raised $20.5 million series B funding to support Neflamapimod, the phase 2b program of its Alzheimer treatment. The funding is also to build the team and to support other research studies related to central nervous system disorders.
- Source: Ddu
- 595
- May 18, 2018
Alzheimer's disease Clinical Trials
Epigenetic Dysregulation May Be Key to Onset

Greater than 90% of all Alzheimer’s disease (AD) cases are sporadic, meaning there are few hereditary risk factors for developing the disease. Although certain genetic variants increase the risk of AD, age is the strongest known risk factor. Yet, understanding how the underlying molecular mechanisms of aging predispose individuals to AD has remained elusive. Now, a team of researchers from the Perelman School of Medicine at the University of Pennsylvania have discovered what they believe are changes to the normal epigenetic landscape that lead to the onset of Alzheimer’s.
- Source: Pixabay
- 609
- March 9, 2018
Alzheimer's Researches
Body clock disruptions occur years before memory loss in Alzheimer’s

Washington University School of Medicine sleep specialist Yo-El Ju, MD, led a research team that found circadian rhythm disruptions occur in people whose memories are intact but whose brain scans show early, preclinical evidence of Alzheimer's disease. She previously had discovered that people with clinical symptoms of Alzheimer's have disturbances in their internal body clocks that affect the sleep/wake cycle. Credit: Washington University School of Medicine.
- Source: medicalxpress
- 640
- February 1, 2018
Alzheimer's disease circadian rhythm disruptions Researches
Alzheimer’s Drug Turns Back Clock in Powerhouse of Cell

The experimental drug J147 is something of a modern elixir of life; it’s been shown to treat Alzheimer’s disease and reverse aging in mice and is almost ready for clinical trials in humans.
- Source: Neuroscience News
- 617
- January 12, 2018
Alzheimer's disease Clinical Trials Researches
Amgen, Novartis Rev Up for New Alzheimer’s Study

Amgen and Basel, Switzerland-based Novartis announced they have expanded their collaboration with the Banner Alzheimer’s Institute (BAI) to launch a new clinical trial in Alzheimer’s.
- Source: Pharmalive
- 708
- November 6, 2017
Alzheimer's API Clinical Trial Market Views
Alzheimer’s–Brain’s protective mechanism revealed

Buildups of "clumpy" proteins in the brain are well-known hallmarks of Alzheimer's, but not everyone who has them goes on to develop this neurodegenerative disease. Why is that? New research investigates.
- Source: medicalnewstoday
- 644
- October 30, 2017
Alzheimer's dendritic spines neurodegenerative Researches

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.